Elan Inks $204M Deal In Zonegran Off-Label Probe

Law360, New York (July 16, 2010, 11:51 AM EDT) -- Irish drugmaker Elan Corp. PLC has said it will pay $203.5 million and plead guilty to a misdemeanor criminal charge to settle a federal investigation into its sales and marketing practices for the epilepsy drug Zonegran.

Elan said Thursday it had reached an agreement in principle with the U.S. Attorney's Office for the District of Massachusetts to settle all federal and state Medicaid claims over its off-label marketing of the drug.

The Dublin-based company's U.S. subsidiary, Elan Pharmaceuticals Inc., expects to plead guilty to a misdemeanor...
To view the full article, register now.